All six panelists discuss their own issues surrounding the need for common, reliable diagnostics and a simple way to explain them. Whether it is Becky Taub discussing liver enzyme levels in F2 and F3 patients in clinical trials, Michael Fuchs stating his belief that institutions need to focus more actively on NAFLD and NASH in their screening, or Louise Campbell and Stephen Harrison discussing why we will need better tests and clearer data and messages to motivate patients, all the Surfers agree that diagnostics and triage are key to improving Fatty Liver treatment.

This conversation is sponsored with a grant from Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is leading the field of NASH therapeutic development with resmetirom, a thyroid receptor beta agonist with potential to address both the liver pathophysiology and fibrosis caused by NASH.

TOPICS: AASLD, cirrhosis, Diabetes, Diagnostic Tests, DrugTrial, education, Fatty Liver, FDA, Global Liver Institute, Madrigal, NAFLD, NASH, non-invasive liver testing, Obesity, Patient Advocacy, PNAFLD, social policy,

Surfing The NASH Tsunami is brought to you by HEP Dynamics
#HEPdynamics #SurfingNASH #podcast